A Phase 2 Study of Ac-225 Rosopatamab Tetraxetan (CONVO1-Alpha) in People With Advanced Prostate Cancer

In the U.S.

Full Title

A Phase 2, Open-label Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants with PSMA PET-Positive Castration-Resistant Prostate Cancer

Purpose

Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called castration-resistant prostate cancers (CRPC).

Researchers are doing this study to assess Ac-225 rosopatamab tetraxetan (also called CONVO1-alpha) in people with CRPC. The people in this study have CRPC cells with prostate-specific membrane antigen (PSMA) on them. PSMA is usually found on normal prostate cells, but is found in higher amounts on prostate cancer cells.

CONV01-alpha is made up of two components. It includes Ac-225, a metal that emits radiation. It also includes rosopatamab tetraxetan, a drug that targets PSMA. When CONV01-alpha binds to PSMA on cancer cells, it causes damage that kills the cancer cell. CONVO1-alpha is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

Have CRPC containing PSMA.
Have completed prior anti-cancer treatments at least 4 weeks before getting the study therapy.
Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
Be age 18 or older.